Beauvericin
Based on 1 publication(s) in Google Scholar
Beauvericin is a cyclohexapeptide Fusarium toxin with insecticidal, antibacterial, anticancer, antiviral and cytotoxic activities. Beauvericin causes cellular genotoxicity by producing DNA breaks, chromosomal aberrations and micronuclei, and inhibits the PI3K/AKT pathway to induce apoptosis, thereby inhibiting the growth of HCC. In addition, Beauvericin affects immune function by inhibiting lymphocyte proliferation and interfering with the differentiation process of human monocytes into macrophages.
For research use only. We do not sell to patients.
- Purity : 99.97%
- CAS No.: 26048-05-5
- Formula: C45H57N3O9
- Molecular Weight:783.95
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Publications Citing Use of MedChemExpress (MCE) Beauvericin
More
Biological Activity
Description
IC50 & Target
|
ACAT |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HepG2 | IC50 |
1 μM
Compound: 12
|
Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 48 hr by CCK-8 assay
Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 48 hr by CCK-8 assay
|
[PMID: 36288556] |
| Huh-7 | IC50 |
4.3 μM
Compound: 12
|
Antiproliferative activity against human Huh-7 cells assessed as reduction in cell viability after 48 hr by CCK-8 assay
Antiproliferative activity against human Huh-7 cells assessed as reduction in cell viability after 48 hr by CCK-8 assay
|
[PMID: 36288556] |
In Vitro
Beauvericin (0-20 μM; 12, 24 and 36 h) has a strong antiproliferative activity against H22 hepatoma cells and promotes apoptosis of H22 hepatoma cells[5]. Beauvericin (50 μM; 72 h) induces apoptosis in turkey peripheral mononuclear cells[6]. Beauvericin (0.3-100 µM) reversibly inhibits L-type voltage-dependent Ca2+ current (ICa,L) in NG108-15 neuronal cells in a concentration-dependent manner with an IC50 value of 4 µM[7]. Beauvericin has IC50 values of 1.0 µM, 2.9 µM, and 2.5 µM for immature dendritic cells, mature dendritic cells, and macrophages, respectively[8]. Beauvericin (1.6 and 2.4 µM; 2 d) reduces CCR7 expression and increases IL-10 secretion in maturing dendritic cells[8]. Beauvericin is a potent inhibitor of CYP3A1/2 in rat liver microsomes (IC50=1.3 mM)[9].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:H22 liver cancer cells
-
Concentration:0, 1, 3, 5,10,15 and 20 µM
-
Incubation Time:12、24 and 36 h
-
Result:Inhibited the growth of H22 cells in a dose-dependent manner.
-
Cell Line:H22 liver cancer cells
-
Concentration:0, 1, 3, 5,10,15 and 20 µM
-
Incubation Time:12、24 and 36 h
-
Result:Upregulated the Bax/Bcl-2 ratio and the levels of cleaved caspase-9 and cleaved caspase-3, and downregulated the p-PI3K/PI3K ratio and p-AKT/AKT ratio.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c mice injected subcutaneously with mouse CT-26 colon cancer cells on the right side[3]
-
Dosage:5 mg/kg
-
Administration:ntraperitoneal injection (i.p.);The drug was administered on the third day after the injection of colon cancer cells and continued once a day for five days, then stopped for two days of observation, and continued on the tenth day after the injection of colon cancer cells, and continued once a day for four days.
-
Result:Reduced the average tumor volume by 52.8 % and the average tumor weight by 60 %.
-
Animal Model:Human cervical cancer KB-3-1 xenograft mouse model[3]
-
Dosage:5 mg/kg
-
Administration:Intraperitoneal injection (i.p.); The drug was administered once a day starting on the fifth day after cervical cancer injection for five days, followed by two days of observation. The drug was administered once a day starting on the twelfth day after cervical cancer cell injection for four days.
-
Result:Reduced the average tumor volume by 31.3 % and the average tumor weight by 31.2 %.
Chemical Information
-
CAS No. 26048-05-5
-
Appearance Solid
-
Molecular Weight 783.95
-
Formula C45H57N3O9
-
Color White to off-white
-
SMILES
CN([C@H](C(O[C@](C(N([C@H](C(O[C@@H]1C(C)C)=O)CC2=CC=CC=C2)C)=O)([H])C(C)C)=O)CC3=CC=CC=C3)C([C@H](OC([C@@H](N(C1=O)C)CC4=CC=CC=C4)=O)C(C)C)=O
-
Structure Classification
-
Initial Source
Fusarium proliferatum,F. semitectum, and F. subglutinans
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (1)
-
Journal Impact Factor
-
Most Recent
Solvent & Solubility
In Vitro:
DMSO : 100 mg/mL (127.56 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
CFSE Dye Dilution Proliferation Assay
The CFSE (carboxyfluorescein diacetate succinimidyl ester) dye dilution proliferation assay is based on the covalent labeling of intracellular proteins by a cell-permeant fluorescent dye that becomes fluorescent upon intracellular ester cleavage and then is stably retained within cells. As labeled cells divide, the dye is partitioned equally between daughter cells, resulting in a stepwise halving of fluorescence intensity that can be quantified by flow cytometry to determine the number of cell divisions undergone by each cell population. This fluorescence dilution approach enables quantitative tracking of lymphocyte proliferation at the single-cell level over multiple rounds of division. CFSE-based proliferation analysis has been widely applied to measure antigen-driven lymphocyte expansion in vitro, where discrete fluorescence peaks correspond to successive cell divisions and allow reconstruction of proliferative history within heterogeneous populations.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Liver Cancer Modeling
Liver cancer can be classified into primary liver cancer and secondary liver cancer. Secondary liver cancer is the metastatic liver cancer. Primary liver cancer includes hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC) and fibrolamellar HCC, of which HCC is the most common form, accounting for approximately 90% of primary liver cancers[1]. HCC mouse models include chemical agent-induced models, transplanted tumor models, and genetic engineered models.
-
Genotoxicity/Mutagenicity Study
The bacterial reverse mutation assay detects point mutations that restore amino-acid prototrophy in auxotrophic Salmonella typhimurium or Escherichia coli tester strains; after exposure to a test article, mutagenic activity is read out as an increased number of revertant colonies on minimal agar compared with the vehicle control. The assay uses tester strains with different mutation targets so that base-substitution and frameshift mutagens can be detected, and testing is performed with and without exogenous mammalian metabolic activation because some chemicals require biotransformation to become mutagenic.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
-
Data Sheet (287 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Handling Instructions (2659 KB)
References
[1]. Mallebrera B, et al. In vitro mechanisms of Beauvericin toxicity: A review[J]. Food and Chemical Toxicology, 2018, 111: 537-545. [Content Brief]
[2]. Wang Q, et al. Beauvericin, a bioactive compound produced by fungi: a short review[J]. Molecules, 2012, 17(3): 2367-2377. [Content Brief]
[3]. Heilos D, et al. The natural fungal metabolite beauvericin exerts anticancer activity in vivo: a pre-clinical pilot study[J]. Toxins, 2017, 9(9): 258. [Content Brief]
[5]. Wang G, et al. Beauvericin exerts an anti-tumor effect on hepatocellular carcinoma by inducing PI3K/AKT-mediated apoptosis[J]. Archives of Biochemistry and Biophysics, 2023, 745: 109720. [Content Brief]
[6]. Dombrink-Kurtzman M A. Fumonisin and beauvericin induce apoptosis in turkey peripheral blood lymphocytes[J]. Mycopathologia, 2003, 156: 357-364. [Content Brief]
[7]. Wu S N, et al. Block of L-type Ca2+ current by beauvericin, a toxic cyclopeptide, in the NG108-15 neuronal cell line[J]. Chemical research in toxicology, 2002, 15(6): 854-860. [Content Brief]
[8]. Ficheux A S, et al. Effects of beauvericin, enniatin b and moniliformin on human dendritic cells and macrophages: An in vitro study[J]. Toxicon, 2013, 71: 1-10. [Content Brief]
[9]. Mei L, et al. An inhibition study of beauvericin on human and rat cytochrome P450 enzymes and its pharmacokinetics in rats[J]. Journal of enzyme inhibition and medicinal chemistry, 2009, 24(3): 753-762. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.2756 mL | 6.3780 mL | 12.7559 mL | 31.8898 mL |
| 5 mM | 0.2551 mL | 1.2756 mL | 2.5512 mL | 6.3780 mL | |
| 10 mM | 0.1276 mL | 0.6378 mL | 1.2756 mL | 3.1890 mL | |
| 15 mM | 0.0850 mL | 0.4252 mL | 0.8504 mL | 2.1260 mL | |
| 20 mM | 0.0638 mL | 0.3189 mL | 0.6378 mL | 1.5945 mL | |
| 25 mM | 0.0510 mL | 0.2551 mL | 0.5102 mL | 1.2756 mL | |
| 30 mM | 0.0425 mL | 0.2126 mL | 0.4252 mL | 1.0630 mL | |
| 40 mM | 0.0319 mL | 0.1594 mL | 0.3189 mL | 0.7972 mL | |
| 50 mM | 0.0255 mL | 0.1276 mL | 0.2551 mL | 0.6378 mL | |
| 60 mM | 0.0213 mL | 0.1063 mL | 0.2126 mL | 0.5315 mL | |
| 80 mM | 0.0159 mL | 0.0797 mL | 0.1594 mL | 0.3986 mL | |
| 100 mM | 0.0128 mL | 0.0638 mL | 0.1276 mL | 0.3189 mL |